Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

The cellular origins of drug resistance in cancer

Nature Medicine volume 22, pages 232–234 (2016)Cite this article

Subjects

Two new studies show that mechanisms of acquired resistance to targeted therapy in lung cancer do not necessarily pre-exist in resistant subclones. Instead, some cancers may harbor the potential to acquire a variety of drug-resistance mechanisms after response to targeted therapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Differing biologies of acquired drug resistance.

Marina Corral Spence/Nature Publishing Group

References

  1. Hata, A.N. et al. Nat. Med. 22, 262–269 (2016).

    Article  CAS  Google Scholar 

  2. Ramirez, M. et al. Nat. Commun. 7, 10.1038/ncomms10690 (19 February 2016).

  3. Arcila, M.E. et al. Clin. Cancer Res. 17, 1169–1180 (2011).

    Article  CAS  Google Scholar 

  4. Zhou, W. et al. Nature 462, 1070–1074 (2009).

    Article  CAS  Google Scholar 

  5. Chmielecki, J. et al. Sci. Transl. Med. 3, 90ra59 (2011).

    Article  CAS  Google Scholar 

  6. Jänne, P.A. et al. N. Engl. J. Med. 372, 1689–1699 (2015).

    Article  Google Scholar 

  7. Ye, X., et al. J. Thorac. Oncol. 8, 1118–1120 (2013).

    Article  Google Scholar 

  8. Sharma, S.V. et al. Cell 141, 69–80 (2010).

    Article  CAS  Google Scholar 

  9. Engelman, J.A. et al. Science 316, 1039–1043 (2007).

    Article  CAS  Google Scholar 

  10. Tricker, E.M. et al. Cancer Discov. 5, 960–971 (2015).

    Article  CAS  Google Scholar 

  11. Oxnard, G.R. et al. Clin. Cancer Res. 20, 1698–1705 (2014).

    Article  CAS  Google Scholar 

  12. Thress, K.S. et al. Nat. Med. 21, 560–562 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Geoffrey R. Oxnard is at the Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.,

    Geoffrey R Oxnard

Authors
  1. Geoffrey R Oxnard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Geoffrey R Oxnard.

Ethics declarations

Competing interests

G.R.O. has received consulting fees from Ariad, AstraZeneca, Boehringer-Ingehleim, Clovis and Genentech.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oxnard, G. The cellular origins of drug resistance in cancer. Nat Med 22, 232–234 (2016). https://doi.org/10.1038/nm.4058

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.4058

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer